A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Phase of Trial: Phase I
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Necitumumab (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 17 Apr 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Jun 2018.
- 25 Mar 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Apr 2017 as reported by ClinicalTrials.gov record.